$6.18
10.64% yesterday
Nasdaq, Nov 15, 10:19 pm CET
ISIN
US75629V1044
Symbol
RXRX
Sector
Industry

Recursion Pharmaceuticals Stock News

Neutral
GlobeNewsWire
3 days ago
Update call scheduled for November 20th at 7:30 a.m. Eastern with anticipated close Update call scheduled for November 20th at 7:30 a.m. Eastern with anticipated close
Neutral
GlobeNewsWire
3 days ago
OpenPhenom is a non-commercial, publicly available foundation model built on microscopy data that has set the new "gold standard" outperforming CellProfiler OpenPhenom is a non-commercial, publicly available foundation model built on microscopy data that has set the new "gold standard" outperforming CellProfiler
Positive
The Motley Fool
14 days ago
In an environment where the typical small biotech name is riskier than not, this one is curiously different.
Neutral
GlobeNewsWire
17 days ago
Company plans to host update call on Nov 20, 2024 after the anticipated close of the proposed business combination with Exscientia Company plans to host update call on Nov 20, 2024 after the anticipated close of the proposed business combination with Exscientia
Positive
The Motley Fool
21 days ago
This company stands to benefit from a shifting pharmaceutical industry landscape.
Neutral
GlobeNewsWire
25 days ago
SALT LAKE CITY, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that the first patient has been dosed in its Phase 2 clinical trial of REC-3964, a potential first-in-class, oral small molecule and new chemical entity for the treatment of recurrent Clostridioides difficile infection....
Positive
The Motley Fool
30 days ago
The key word here is "could."
Positive
The Motley Fool
about one month ago
Wood has a stake in this stock, but it's hardly an "all-in" bet.

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today